Product Description: SB-265610 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis with IC50s of 3.7 nM and 70 nM, respectively[1][2].
Applications: Neuroscience-Neuromodulation
Formula: C14H9BrN6O
References: [1]Auten RL, et al. Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J Pharmacol Exp Ther. 2001 Oct;299(1):90-5./[2]Milatovic S, et al. Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen. 2003 May-Jun;11(3):213-9./[3]Li Yang, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008 Jan;13(1):23-35.
CAS Number: 211096-49-0
Molecular Weight: 357.16
Compound Purity: 99.0
Research Area: Inflammation/Immunology
Solubility: DMSO : 33.33 mg/mL (ultrasonic;warming;heat to 60°C)
Target: CXCR
Deutsch
English
